[1] Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors[J]. J Am Med Assoc, 1957, 163(13): 1117-1124. DOI: 10.1001/jama.1957.02970480021005.
[2] Fukunaga H, Engel AG, Lang B, et al. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones[J]. Proc Natl Acad Sci U S A, 1983, 80(24): 7636-7640. DOI: 10.1073/pnas.80.24.7636.
[3] O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases[J]. Brain, 1988, 111 (Pt 3): 577-596. DOI: 10.1093/brain/111.3.577.
[4] Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes[J]. N Engl J Med, 1995, 332(22):1467-1474. DOI: 10.1056/NEJM199506013322203.
[5] Hülsbrink R, Hashemolhosseini S. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy[J]. Clin Neurophysiol, 2014, 125(12): 2328-2336. DOI: 10.1016/j.clinph.2014.06.031.
[6] Tarr TB, Wipf P, Meriney SD. Synaptic pathophysiology and treatment of lambert-eaton myasthenic syndrome[J]. Mol Neurobiol, 2015, 52(1): 456-463. DOI: 10.1007/s12035-014-8887-2.
[7] Schoser B, Eymard B, Datt J, et al. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer[J]. J Neurol, 2017, 264(9): 1854-1863. DOI: 10.1007/s00415-017-8541-9.
[8] Punga AR, Maddison P, Heckmann JM, et al. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders[J]. Lancet Neurol, 2022, 21(2): 176-188. DOI: 10.1016/S1474-4422(21)00297-0.
[9] Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies[J]. Lancet Neurol, 2011, 10(12): 1098-1107. DOI: 10.1016/S1474-4422(11)70245-9.
[10] Ivanovski T, Miralles F. Lambert-Eaton Myasthenic syndrome: early diagnosis is key[J]. Degener Neurol Neuromuscul Dis, 2019, 9: 27-37. DOI: 10.2147/DNND.S192588.
[11] Stålberg E. Neurophysiological aspects of diagnosis in neuromuscular transmission defects--an update[J]. Electroencephalogr Clin Neurophysiol Suppl, 1999, 50: 377-385.
[12] AAEM Quality Assurance Committee. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome[J]. Muscle Nerve, 2001, 24(9):1239-1247. DOI: 10.1002/mus.1140.
[13] Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients[J]. Ann N Y Acad Sci, 1998, 841: 823-826. DOI: 10.1111/j.1749-6632.1998.tb11024.x.
[14] Oh SJ, Kurokawa K, Claussen GC, et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome[J]. Muscle Nerve, 2005, 32(4): 515-520. DOI: 10.1002/mus.20389.
[15] Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome[J]. Muscle Nerve, 2008, 37(5): 572-575. DOI: 10.1002/mus.20979.
[16] Wirtz PW, Smallegange TM, Wintzen AR, et al. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases[J]. Clin Neurol Neurosurg, 2002, 104(4): 359-363. DOI: 10.1016/s0303-8467(02)00054-9.
[17] Titulaer MJ, Wirtz PW, Willems LN, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome[J]. J Clin Oncol, 2008, 26(26):4276-4281. DOI: 10.1200/JCO.2008.17. 5133.
[18] Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS[J]. J Clin Oncol, 2011, 29(7): 902-908. DOI: 10.1200/JCO.2010. 32.0440.
[19] Maddison P, Lipka AF, Gozzard P, et al. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort[J]. Sci Rep, 2020, 10(1): 10546. DOI: 10.1038/s41598-020-67571-9.
[20] Sanders DB, Juel VC, Harati Y, et al. 3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia[J]. Muscle Nerve, 2018, 57(4):561-568. DOI: 10.1002/mus.26052.
[21] Sanders DB. Lambert-eaton myasthenic syndrome: diagnosis and treatment[J]. Ann N Y Acad Sci, 2003, 998: 500-508. DOI: 10.1196/annals.1254.065.
[22] Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders[J]. Eur J Neurol, 2010, 17(7): 893-902. DOI: 10.1111/j.1468-1331.2010.03019.x.
[23] Lee JC, Yamauchi H, Hopper J. The association of cancer and the nephrotic syndrome[J]. Ann Intern Med, 1966, 64(1):41-51. DOI: 10.7326/0003-4819-64-1-41.
[24] Wirtz PW, van Dijk JG, van Doorn PA, et al. The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands[J]. Neurology, 2004, 63(2): 397-398. DOI: 10.1212/01.wnl.0000130254.27019.14.
[25] Abenroth DC, Smith AG, Greenlee JE, et al. Lambert-Eaton myasthenic syndrome: epidemiology and therapeutic response in the national veterans affairs population[J]. Muscle Nerve, 2017, 56(3):421-426. DOI: 10.1002/mus.25520.
[26] Yoshikawa H, Adachi Y, Nakamura Y, et al. Nationwide survey of Lambert-Eaton myasthenic syndrome in Japan[J]. BMJ Neurol Open, 2022, 4(2): e000291. DOI: 10.1136/bmjno-2022-000291.
[27] Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment[J]. Neurology, 2000, 54(11):2176-2178. DOI: 10.1212/wnl.54.11.2176.
[28] Lipka AF, Boldingh MI, van Zwet EW, et al. Long-term follow-up, quality of life, and survival of patients with Lambert-Eaton myasthenic syndrome[J]. Neurology, 2020, 94(5): e511-e520. DOI: 10.1212/WNL.0000000000008747.
|
